Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127421131 | 12742113 | 1 | I | 20160908 | 20160914 | 20160914 | PER | PHEH2016US022755 | NOVARTIS | 0.00 | F | Y | 0.00000 | 20160914 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127421131 | 12742113 | 1 | PS | ZOMETA | ZOLEDRONIC ACID | 1 | Oral | U | 21223 | ||||||||||
| 127421131 | 12742113 | 2 | SS | REVLIMID | LENALIDOMIDE | 1 | Oral | 25 MG, QD (FOR 14 DAYS EVERY CYCLE) | 0 | 25 | MG | QD | |||||||
| 127421131 | 12742113 | 3 | SS | REVLIMID | LENALIDOMIDE | 1 | Oral | 10 MG, QD (28 IN 29 DAYS) | 0 | 10 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127421131 | 12742113 | 1 | Product used for unknown indication |
| 127421131 | 12742113 | 2 | Plasma cell myeloma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127421131 | 12742113 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127421131 | 12742113 | Malaise | |
| 127421131 | 12742113 | Renal failure |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127421131 | 12742113 | 2 | 201605 | 0 | ||
| 127421131 | 12742113 | 3 | 201606 | 0 |